E-ISSN 2231-3206 | ISSN 2320-4672
 
2024, Vol: 14, Issue: 4
14 / 4Current Issue Online FirstArchiveAims and ScopeAbstracting & IndexingMost Accessed ArticlesMost Downloaded ArticlesMost Cited Articles
Required files to be uploaded

Authorship Declaration

Original Research

Online Publishing Date:
31 / 01 / 2022

 


Real-world observational study of escitalopram for newly diagnosed versus relapsed patients with major depressive disorder in India

Saili Dharadhar, Amit Sharma, Sagar Karia.


Abstract
Background: Depression is common yet under-reported disorder in the real-world setting. Although antidepressants have demonstrated superiority over placebo in clinical trials, many patients elicit a suboptimal response or relapse. Moreover, real-world data in the Indian population are limited.

Aim and Objective: This study aims to assess and compare the efficacy and safety of escitalopram in patients with newly diagnosed depression (NDD) versus relapse in India.

Materials and Methods: This is an ongoing real-world observational study of escitalopram in patients with NDD or relapse in India. Primary endpoint was change in mean Hamilton Depression Rating Scale (HAM-D 17) scores from baseline to week 8. Secondary endpoints included assessment of response/remission rates, Clinical Global Impression (CGI) scores, quality of life, suicidal tendency, and safety.

Results: Data for the first 50 patients demonstrated a significant reduction in HAM-D 17 scores at week 8 (P < 0.001); patients with NDD (n = 38) elicited significantly higher improvement compared with relapsed patients (n = 12) (P < 0.001). Although patients with NDD had significantly poorer CGI (P < 0.001) and quality of life (anxiety/depression subscale) (P < 0.05) scores at baseline, an improvement was observed in both scales with no significant difference between the groups at week 8. Suicidal tendency reduced from 83.3% to 0%. No new safety concerns were observed in the study.

Conclusion: Escitalopram demonstrated efficacy and was well tolerated in both, NDD and relapsed patients in the real-world setting in India, with better results achieved by NDD patients. However, more studies are required to confirm the difference across the groups.

Key words: Depression; India; Major Depressive Disorder; Observational Study; Real World; Relapse


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Saili Dharadhar
Articles by Amit Sharma
Articles by Sagar Karia
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Dharadhar S, Sharma A, Karia S. Real-world observational study of escitalopram for newly diagnosed versus relapsed patients with major depressive disorder in India. Natl J Physiol Pharm Pharmacol. 2022; 12(9): 1399-1407. doi:10.5455/njppp.2022.12.124668202119012022

Web Style

Dharadhar S, Sharma A, Karia S. Real-world observational study of escitalopram for newly diagnosed versus relapsed patients with major depressive disorder in India. https://www.njppp.com/?mno=139532 [Access: March 14, 2024]. doi:10.5455/njppp.2022.12.124668202119012022

AMA (American Medical Association) Style

Dharadhar S, Sharma A, Karia S. Real-world observational study of escitalopram for newly diagnosed versus relapsed patients with major depressive disorder in India. Natl J Physiol Pharm Pharmacol. 2022; 12(9): 1399-1407. doi:10.5455/njppp.2022.12.124668202119012022


Vancouver/ICMJE Style

Dharadhar S, Sharma A, Karia S. Real-world observational study of escitalopram for newly diagnosed versus relapsed patients with major depressive disorder in India. Natl J Physiol Pharm Pharmacol. (2022), [cited March 14, 2024]; 12(9): 1399-1407. doi:10.5455/njppp.2022.12.124668202119012022


Harvard Style

Dharadhar, S., Sharma, . A. & Karia, . S. (2022) Real-world observational study of escitalopram for newly diagnosed versus relapsed patients with major depressive disorder in India. Natl J Physiol Pharm Pharmacol, 12 (9), 1399-1407. doi:10.5455/njppp.2022.12.124668202119012022


Turabian Style

Dharadhar, Saili, Amit Sharma, and Sagar Karia. 2022. Real-world observational study of escitalopram for newly diagnosed versus relapsed patients with major depressive disorder in India. National Journal of Physiology, Pharmacy and Pharmacology, 12 (9), 1399-1407. doi:10.5455/njppp.2022.12.124668202119012022


Chicago Style

Dharadhar, Saili, Amit Sharma, and Sagar Karia. "Real-world observational study of escitalopram for newly diagnosed versus relapsed patients with major depressive disorder in India." National Journal of Physiology, Pharmacy and Pharmacology 12 (2022), 1399-1407. doi:10.5455/njppp.2022.12.124668202119012022


MLA (The Modern Language Association) Style

Dharadhar, Saili, Amit Sharma, and Sagar Karia. "Real-world observational study of escitalopram for newly diagnosed versus relapsed patients with major depressive disorder in India." National Journal of Physiology, Pharmacy and Pharmacology 12.9 (2022), 1399-1407. Print. doi:10.5455/njppp.2022.12.124668202119012022


APA (American Psychological Association) Style

Dharadhar, S., Sharma, . A. & Karia, . S. (2022) Real-world observational study of escitalopram for newly diagnosed versus relapsed patients with major depressive disorder in India. National Journal of Physiology, Pharmacy and Pharmacology, 12 (9), 1399-1407. doi:10.5455/njppp.2022.12.124668202119012022


Author LoginReviewer LoginAbout PublisherEditorial PoliciesEditorial Review PolicyPeer Review PolicyEditorial & Peer Review ProcessPublication Ethics and Publication Malpractice StatementConflict of Interest PolicyPlagiarism PolicyProtection of Research Participants (Statement On Human And Animal Rights)Corrections, Retractions & Expressions of ConcernSelf-Archiving PoliciesStatement of Informed ConsentAdvertising PolicyTerms of UseLicense InformationCopyright Information

About National Journal of Physiology, Pharmacy and Pharmacology

  National Journal of Physiology, Pharmacy and Pharmacology is a monthly peer reviewed journal.  The journal is having open access polic ... Read more.



For best results, please use Internet Explorer or Google Chrome.

Contact Information


Publisher

publishernjppp@gmail.com

 

Editorial query

editornjppp1@gmail.com

MOB - 8780040272